Stada Gets FDA Nod For US Epoetin Alfa Supply

Adds US Market To Existing European Supply Deal With Pfizer For Epogen/Procrit Biosimilar

 
• By Dave Wallace

Stada has received US FDA approval to supply the Retacrit epoetin alfa biosimilar to partner Pfizer for the US market, allowing it to expand on an existing European supply arrangement.

Stada_Arzneimittel
Stada is expanding a supply partnership for epoetin alfa

More from Biosimilars

More from Products